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Introduction: Traditional carotid endarterectomy is considered to be the standard technique for preven-
tion of a new stroke in patients with a symptomatic carotid stenosis. Use of plexus anesthesia or general
anesthesia in traditional carotid endarterectomy is, to date, not unequivocally proven to be superior to
one other. A systematic review is needed for evaluation of benefits and harms to determine which tech-
nique, plexus anesthesia or general anesthesia is more effective for traditional carotid endarterectomy in
patients with symptomatic carotid stenosis.
Methods and outcomes: The review will be conducted according to this protocol following the recommen-
dations of the ‘Cochrane Handbook for Systematic Reviews’ and reported according to Preferred
Reporting Items for Systematic Reviews and Meta-Analyses. Randomized Clinical Trials comparing plexus
anesthesia versus general anesthesia in traditional carotid endarterectomy will be included. Primary out-
comes will be postoperative death and/ or stroke (<30 days) and serious adverse events. Secondary out-
comes will be non-serious adverse events.
We will primarily base our conclusions on meta-analyses of trials with overall low risk of bias. We will
use Trial Sequential Analysis to assist the evaluation of imprecision in Grading of Recommendations
Assessment, Development and Evaluation. However, if pooled point-estimates of all trials are similar
to pooled point-estimates of trials with overall low risk of bias and there is lack of a statistical significant
interaction between estimates from trials with overall high risk of bias and trials with overall low risk of
bias we will consider the Trial Sequential Analysis adjusted confidence interval precision of the estimate
achieved in all trials as the result of our meta-analyses.
Ethics and dissemination: The proposed systematic review will collect and analyze secondary data from
already performed studies therefore ethical approval is not required. The results of the systematic review
will be disseminated by publication in a peer-review journal and submitted for presentation at relevant
conferences.
 2020 The Author(s). Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).n Aalst),
s@etz.nl
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There is still controversy which type of anesthesia, plexus anes-
thesia (PA) or general anesthesia (GA), is best for carotid
endarterectomy (CEA). Guidelines of both the European Society
of Vascular Surgery and the Dutch Society for Vascular Surgery rec-
ommend that choice of anesthesia for carotid endarterectomy (PA
or GA) be left to the surgical team’s preference [1–3]. Patients pref-
erences or instruct ability could also play a role in the choice of
technique.
The technique of CEA is previously described [4]. When a
patient receives GA, the patient receives an opioid, muscle relaxant
and an intravenous anesthetic such as propofol followed by intuba-
tion and mechanical ventilation [5]. When a patient receives PA a
local anesthetic will be used e.g. ropivacaine. The patient is in a
supine position facing away from the side of the surgery. The anes-
thetic will be put in place with guidance of anatomical landmarks
or with help of an ultrasound by an anesthesiologist. Prior to the
injection of the anesthetic lidocaine–prilocaine is applied to numb
the skin. After skin disinfection the needle will be put in place at
the level of the carotid bifurcation nearby the carotid sheath and
a depot of the anesthetic will be placed superiorly and inferiorly
along the posterior border of the sternocleidomastoid muscle.
The carotid sheath can be numbed using ultra sound by the anes-
thesiologist of during surgery by the vascular surgeon.
Next to the plexus anesthesia, sedation can be considered to
keep the patient comfortable. This sedation may consist of
Dexmedetomidine, the first 10 minutes at 1 mcg/kg/h, after
10 min around 1/3 of the dosage guided by the heart frequency
and or blood pressure. Simultaneously remifentanil is used at
0.1 mcg/kg/min, and after 10 min the dosage is continued at 0.05
lowered by 50%. Noradrenaline can be used to keep the blood pres-
sure within its desired range to keep the brain adequately
perfused.
Each type of anesthesia has its (dis)advantages. PA allows real-
time monitoring compared to using Transcranial Doppler (TCD)
and/or Electroencephalography (EEG) monitoring with GA. TCD
and/or EEGmonitoring are not perfect and assessment may be nor-
mal in 6% to 30% of those who develop neurological signs and
abnormal in 3% to 11% of those who do not develop signs of ische-
mia [6]. Another advantage of PA is that the awake state of the
patient does not impair the blood pressure regulation in contrast
to GA, which may lower the risk of a periprocedural stroke [7].
PA is associated with a lower incidence of shunt placement during
carotid endarterectomy [8]. The use of a shunt can prevent a peri-
operative ischemic event. However, it can cause damage to the
arterial wall and/or cause an ischemic event [6]. Patients may have
less post procedural pain compared with those after GA [9]. The
main disadvantage of PA is conversion to GA, which can be neces-
sary when the patient experiences too much pain. PA could also
numb the phrenic nerve which can lead to intubation of patients
with an already impaired pulmonary function. Other reasons for
conversion to general anesthesia can be e.g. claustrophobia, airway
obstruction due to cervical hematoma, loss of consciousness at car-
otid clamping, and shunt-related complications [10]. incidences of
operative complications, such as local hemorrhage, cranial nerve
damage, and pulmonary complications have been reported for
both PA and GA and showed no differences [11].
Preventive management of (a)symptomatic carotid artery
stenosis includes antiplatelet therapy, statins, antihypertensive
therapy, diabetic control, as well as lifestyle modifications [11–
14]. When a patient shows symptoms, different operation tech-
niques are available and described in literature such as carotid
endarterectomy with primary closure, eversion technique and tra-
ditional carotid endarterectomy with patch closure. CarotidDownloaded for Anonymous User (n/a) at University of Gron
For personal use only. No other uses without permissioendarterectomy with patch angioplasty is the preferred guideline
treatment for patients with symptomatic stenosis of the carotid
artery [14,16], primarily based on the European Carotid Surgery
Trial (ECST) and the North American Symptomatic Carotid
Endarterectomy Trial (NASCET) [1,4,17,18].
A multicenter, randomized clinical trial (RCT) included 3523
operations in 3523 symptomatic and asymptomatic patients and
compared PA with GA and concluded that there was no significant
difference between the two techniques for stroke (including retinal
infarction), myocardial infarction, and death between randomiza-
tion and 30 days after surgery [7]. However, the observed differ-
ence or lack of difference may or may not be affected by several
confounding factors and/or differential use of co-interventions,
such as the use of different surgical techniques, selected use of
shunting, and variations in materials used for patching [18,20].
Previous conducted systematic reviews with meta-analysis of
the randomized trials showed that there was no statistically signif-
icant difference between the PA and GA groups in the proportion of
patients who had a stroke, died, or had a myocardial infarction
within 30 days of carotid endarterectomy [10,21]. These reviews
were conducted without Trial Sequential Analysis (TSA). To con-
firm or reject meta-analysis results we will add and TSA and
include Grading of Recommendations Assessment, Development
and Evaluation (GRADE) assessments of the evidence. We also try
to reduce clinical heterogeneity by comparing only technique
(PA) with one other technique (GA) in patients for carotid
endarterectomy with patch angioplasty and also reduce the risk
for random error.
To determine which technique, PA or GA is more effective for
carotid endarterectomy with patch angioplasty in symptomatic
carotid stenosis from the patients’ perspective, it is important that
all available evidence is evaluated according to the risks of errors in
a systematic review in line with the Cochrane Handbook for Sys-
tematic Reviews of Interventions [21,23]. Therefore, an updated
systematic review with meta-analyses is needed.1.1. Objective
The objective is to conduct a systematic review with meta-
analysis and Trial Sequential Analysis of randomized clinical trials,
evaluating the benefits and harms of plexus anesthesia versus gen-
eral anesthesia in carotid endarterectomy with patch angioplasty
according to a pre-published protocol based on aspects of the
Cochrane Handbook for Systematic Reviews of Interventions [22].2. Methods
This review will be conducted according to this protocol, regis-
tered at PROSPERO CRD42019139913 [24] based on aspects of the
recommendations of the ‘Cochrane Handbook for Systematic
Reviews of interventions’ [22] and will be reported according to
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement (www.prisma-statement.org) [25].2.1. Studies
According to the current guideline [1,17,18] patients with a
symptomatic stenosis (50 – 99%) of the carotid artery will be
considered. Only trials which evaluate plexus anesthesia versus
general anesthesia in carotid endarterectomy with patch angio-
plasty in adult patients (18 years) will be included [3]. Trials will
be considered irrespective of language, blinding, outcomes, or pub-
lication status.ingen from ClinicalKey.com by Elsevier on July 24, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
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Plexus anesthesia (PA) in carotid endarterectomy with patch
angioplasty.
2.3. Control intervention
General anesthesia (GA) in carotid endarterectomy with patch
angioplasty.
2.4. Hypothesis
We want to test the null-hypothesis that there is no difference
between the two treatments (H0: RRR = 0.00% or RR = 1.00) as well
as both the alternative hypotheses (H1a and H1b) that there is a
difference (H1a of a 10% RRR or H1b of a 15% RRR) between plexus
anesthesia (PA) and general anesthesia (GA) in patients with a
symptomatic carotid lesion. We think that patients operated with
plexus anesthesia will do better because the neurological status
of the patient can be monitored in real time compared with
patients operated with general anesthesia in which the surgeon
depends on a derived monitoring through TCD and EEG.
2.5. Outcomes
The outcome measures will be graded from the patients’ per-
spective (GRADE working group 2008, Fig. 1) [26]. Examples of
serious adverse events: stroke, bleeding, persisting neurological
deficits, myocardial infarction, conversion PA to GA due to any
cause, patients developing airway obstruction or phrenic nerve
palsy and hypertension in need for (intravenous) medication.
2.6. Primary outcomes
 Proportion of participants who suffered death (<30 days).
 Proportion of participants with postoperative stroke
(<30 days).
 Proportion of participants with one or more serious adverse
events; which is defined as: any untoward medical occurrence that
results in death, is life threatening, requires hospitalization orFig. 1. Outcomes prioritized according to importance to patients undergoing
carotid surgery for symptomatic carotid stenosis (GRADE 2008) [26] *<30 days.
Downloaded for Anonymous User (n/a) at University of Groning
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nificant disability or incapacity (or is a congenital anomaly or birth
defect) [27].
2.7. Secondary outcomes
 Proportion of participants with one or more non-serious
adverse events: any untoward medical occurrence in a participant
that does not meet the above criteria for a serious adverse event is
defined as a non-serious adverse event [27].
 Costs: hospitalization duration, duration of surgical proce-
dure, ICU admission (e.g. blood pressure management).
2.8. Exploratory outcomes
 Separately reported serious adverse events.
 Separately reported non-serious adverse events.
The number of patients with one or more complications will be
evaluated rather than the numbers of events, depending on the
availability of data.
2.9. Search strategy
The Cochrane Central Register of Controlled Trials (CENTRAL) in
the Cochrane Library, PubMed/MEDLINE and EMBASE will be
searched. References of the identified trials will be searched to
identify any further relevant randomized clinical trials. The search
strategies are provided in the appendix. Searches will include
MeSH descriptors such as ‘‘Clinical Trials”, ‘‘carotid endarterec-
tomy”, ‘‘plexus”, ‘‘carotid artery disease”, ‘‘anesthesia”, ‘‘patch”.
We will also search online trial registries such as ClinicalTrials.gov
(https://clinicaltrials.gov/), European Medicines Agency (EMA)
(www.ema.europa.eu/ema/), WHO International Clinical Trial Reg-
istry Platform (www.who.int/ictrp), and the Food and Drug Admin-
istration (FDA) (www.fda.gov) for ongoing or unpublished trials. In
addition, we plan to search Google Scholar (https://scholar.google.
nl/) using the terms: anesthesia and/or plexus and/or local anes-
thesia and/or carotid and/or endarterectomy in the title of the
abstract/paper.
2.10. Data collection
Two authors will perform screening and select the trials for
inclusion, independently. Excluded trials and studies will be listed
with their reasons for exclusion. When disagreements should
occur, a third author will be approached to reconcile. The authors
will extract the following data when available: type of anesthesia,
trial characteristics (year and language of publication, country in
which the trial was conducted, year of conduction of the trial, sin-
gle or multicenter trial, number of patients), patient characteristics
(inclusion and exclusion criteria, mean age, mean body mass index
and gender, smoking, diabetes mellitus, use of statin and platelet
inhibitors), intervention characteristics (general anesthesia, plexus
anesthesia, closure by type of patch, use of shunting), co-
interventions (conversion to general anesthesia, perioperative
transcranial Doppler monitoring, perioperative carotid pressure
measurement, electroencephalographic monitoring) and the out-
come measures evaluated. If there are any unclear or missing data,
the corresponding authors of the individual trials will be contacted,
at least twice, for clarification.
2.11. Risk of bias assessment
Two authors will assess the risks of bias, without masking for
trial names, according to the Cochrane Handbook for Systematic
Reviews of Interventions [22], including the domains of generationen from ClinicalKey.com by Elsevier on July 24, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
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ticipants, personnel, and outcome assessors, incomplete outcome
data, selective outcome reporting, and bias risks such as vested
interests (financial interest, academical interest or other parties
such as the medical industry). Risk of bias components will be
scored as low, unclear, or high risk of bias.
2.12. Sequence generation
 Low risk of bias: The method used (e.g. central allocation) is
unlikely to induce bias on the final observed effect, such as:
 referring to a random number table;
 using a computer random number generator;
 coin tossing;
 shuffling cards or envelopes;
 throwing dice;
 drawing of lots.
 Unclear risk of bias: Insufficient information to assess whether
the method used is likely to introduce confounders.
 High risk of bias: The method is improper and likely of intro-
duce confounding, e.g. based on date of admission, or record
number, or by odd or even date of birth.
2.13. Allocation concealment
Some aspects of the conduct of randomized trials, particularly
blinding, are associated with a modest exaggeration of treatment
effects on average, but there is little evidence that the average bias
differs according to whether the outcome was subjectively or
objectively assessed. However, lack of blinding in trials with sub-
jective outcomes leads to increased heterogeneity and hence
unpredictable bias in effect estimates. As far as possible, clinical
and policy decisions should be cautious when they are based on
trials in which blinding was not reported or not feasible and out-
come measures were subjectively assessed [28].
 Low risk of bias: Participants and investigators enrolling par-
ticipants could not foresee assignment because one of the fol-
lowing, or an equivalent method, was used to conceal
allocation:
 central allocation (including telephone);
 web-based and pharmacy-controlled randomization;
 sequentially numbered drug containers of identical
appearance;
 sequentially numbered, opaque, sealed envelopes.
 Unclear risk of bias: Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’. This is usually the case if the
method of concealment is not described or not described in
sufficient detail to allow a definite judgement.
 High risk of bias: Participants or investigators enrolling par-
ticipants could possibly foresee assignments and thus intro-
duce selection bias, such as allocation based on:
 an open random allocation schedule;
 assignment envelopes were used without appropriate
safeguards;
 alternation or rotation;
 date of birth;
 case record number;
 any other explicitly unconcealed procedure.
2.14. Blinding of participants and personnel
In surgical procedures it is impossible to blind the surgeon who
performs the procedure of CEA, while it is possible to blind the
caregivers responsible for postoperative care as well as the patientsDownloaded for Anonymous User (n/a) at University of Gron
For personal use only. No other uses without permissio[29]. In this type of comparison with PA and GA no blinding is pos-
sible. For this domain we cannot consider the surgeon, caregivers
and patients, so a certain risk of bias will inevitably be present
when evaluating surgical procedures.
 Low risk of bias: No blinding or incomplete blinding, but the
review authors judge that the outcome is not likely to be
influenced by lack of blinding or blinding of participants
and key study personnel ensured, and it is unlikely that the
blinding could have been broken.
 Unclear risk of bias: Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’, or the study did not address
this outcome.
 High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding or blind-
ing of key study participants and personnel attempted, but
likely that the blinding could have been broken, and the out-
come is likely to be influenced by lack of blinding.
2.15. Blinding of outcome assessment
 Low risk of bias: No blinding of outcome assessment, but the
review authors judge that the outcome measurement is not
likely to be influenced by lack of blinding or blinding of out-
come assessment is ensured, and it is unlikely that the blind-
ing could have been broken.
 Unclear risk of bias: Insufficient information to permit judge-
ment of ‘Low risk’, or ‘High risk’ or the study did not address
this outcome.
 High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of
blinding, or blinding of outcome assessment, but likely that
the blinding could have been broken, and the outcome mea-
surement is likely to be influenced by lack of blinding.
2.16. Incomplete outcome data
 Low risk of bias:
 no missing outcome data;
 reasons for missing outcome data unlikely to be related to
true outcome (for survival data, censoring unlikely to be
introducing bias);
 missing outcome data balanced in numbers across interven-
tion groups, with similar reasons for missing data across
groups;
 for dichotomous outcome data, the proportion of missing out-
comes compared with observed event risk is not enough to
have a clinically relevant impact on the intervention effect
estimate;
 for continuous outcome data, plausible effect size (difference
in means or standardized difference in means) among miss-
ing outcomes is not enough to have a clinically relevant
impact on observed effect size;
 missing data have been imputed using appropriate methods.
 Unclear risk of bias: Insufficient reporting of attrition/exclu-
sions to permit judgement of ‘Low risk’ or ‘High risk’ (e.g.
number randomized not stated, no reasons for missing data
provided) or the study did not address this outcome.
 High risk of bias:
 reason for missing outcome data likely to be related to true
outcome, with either imbalance in numbers or reasons for
missing data across intervention groups;
 for dichotomous outcome data, the proportion of missing out-
comes compared with observed event risk enough to induce
clinically relevant bias in intervention effect estimate;ingen from ClinicalKey.com by Elsevier on July 24, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
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in means or standardized difference in means) among miss-
ing outcomes enough to induce clinically relevant bias in
observed effect size;
 ‘as-treated’ analysis done with substantial departure of the
intervention received from that assigned at randomization;
 potentially inappropriate application of simple imputation.
2.17. Selective outcome reporting
 Low risk of bias: The study protocol is available and all the
studies pre-specified (primary and secondary) outcomes that
are of interest in the review have been reported in the pre-
specified way, or the study protocol is not available but it is
clear that the published reports include all expected out-
comes, including those that were pre-specified.
 Unclear risk of bias: Insufficient information to permit judge-
ment of ‘Low risk’ or ‘High risk’. It is likely that the majority of
studies will fall into this category.
 High risk of bias:
 not all of the studies pre-specified primary outcomes have
been reported;
 one or more primary outcomes is reported using measure-
ments, analysis methods or subsets of the data (e.g. sub-
scales) that were not pre-specified;
 one or more reported primary outcomes were not pre-
specified (unless clear justification for their reporting is pro-
vided, such as an unexpected adverse effect);
 one or more outcomes of interest in the review are reported
incompletely so that they cannot be entered in a meta-
analysis;
 the study report fails to include results for a key outcome that
would be expected to have been reported for such a study.
2.18. Other bias
 Low risk of bias: The study appears to be free of other sources of
bias.
 Unclear risk of bias: There may be a risk of bias, but there is
either insufficient information to assess whether an important
risk of bias exists or insufficient rationale or evidence that an
identified problem will introduce bias.
 High risk of bias: There is at least one important risk of bias.
2.19. Overall risk of bias
Trials were classified as trials with low overall risk of bias if all
risk of bias domains were scored as having low risk of bias. If one or
more of the bias domains were scored as unclear or high risk of
bias, the trial was considered to have high overall risk of bias. Trials
classified as low risk of bias in all domains of sequence generation,
allocation concealment, blinding, incomplete data, selective out-
come reporting, source of funding and other potential risks of bias
will be considered trials at overall low risk of bias. Trials with one
or more of these domains scored as unclear or high risk of bias will
be considered trials at overall high risk of bias [22,28,30].
2.20. Statistical methods
Meta-analyses will be performed according to the Cochrane
Handbook for Systematic Reviews of Interventions [22]. The soft-
ware package Review Manager (RevMan) Version 5.3 will be used
[31]. Significance levels will be adjusted due to multiplicity of sev-
eral outcomes. The results of each outcome will require an
adjusted statistical significance level (threshold). An alfa of respec-
tively (0.05/((1 + 3)/2) = ) 0.025 will be used for the primary andDownloaded for Anonymous User (n/a) at University of Groning
For personal use only. No other uses without permission. C0.033 for the secondary outcomes to keep the family wise error
rate (FWER) below 0.05 [31,33]. For exploratory outcomes, we will
consider a p-value less than 0.05 as significant, because we view
these outcomes as only hypothesis-generating outcomes. For
dichotomous variables, the risk ratio (RR) with TSA-adjusted confi-
dence intervals (CI) will be calculated. For continuous variables,
the mean difference (MD) with TSA-adjusted CI will be calculated
or the standardized mean difference (SMD) with 95% CI will be
calculated.
For the outcome of SAE we plan to estimate the proportion of
patients with one or more SAE in each group and to analyze this
outcome in a binary meta-analysis. However, as we anticipate
the reporting of SAEs in trials to vary considerably we plan to do
two analyses and to avoid multiple counts of SAE in the same
patients (SAE counting is not a statistical independent outcome):
1) The cumulated SAE analysis: Assuming that only one SAE is
reported per patient. We will summarize all reported SAE in each
trial and calculate the proportion of summed SAE divided with
number of randomized patients in the experimental and control
intervention group, the number of patients in each group will con-
stitute a maximum of SAEs (maximum proportion = 1.00).
2) The highest proportion of SAEs registered: we will analyze
the most frequent SAE in each included trial as if it represents
the total number of patients with SAEs in the experimental and
control intervention group assuming that if a patient don’t get
the SAE with the highest proportion in the trial they don’t get
another SAE either. Being aware that none of these intervention
effect estimates (1 or 2) are exactly correct we will discuss differ-
ences between the effect of the experimental vs the control inter-
vention on the proportion of patients with one or more SAEs.
The impact of attrition bias will be explored using best/ worst
and worst/ best case scenarios: a best/ worst case scenario is one
where all patients lost to follow-up in the intervention group are
supposed to have survived while all patients lost to follow-up in
the control intervention group have died. A worst/best case sce-
nario is the reverse.
Heterogeneity will be explored by chi-squared test with signif-
icance set at p-value of 0.10, and the quantity of heterogeneity will
be measured by I2. We will conduct both random-effects model
and fixed-effect model meta-analyses. In case of discrepancies
the results of both models will be presented and we will primarily
stress the result of the model with the result closest to null effect
due to principle of cautiousness [33]. The analyses will be per-
formed on an intention-to-treat basis whenever possible.
A funnel plot will be used to explore small trial bias and to use
asymmetry in funnel plot of trial size against treatment effect to
assess this bias. Begg’s and Egger’s tests will be used to test for
asymmetry in funnel plots [34].
2.21. Trial Sequential analyses (TSA)
Meta-analyses may result in type-I errors and type-II errors due
to an increased risk of random error when sparse data are analyzed
and due to repeated significance testing when a cumulative meta-
analysis is updated with new trials [34,36]. To assess the risk of
type-I and type-II errors, TSA will be used. The vast majority of
meta analyses (nearly 80%) in Cochrane systematic reviews have
less than the required information size to conclude on a 30% rela-
tive risk reduction (RRR) and less than 2% have sufficient power to
conclude on a 10% RRR [36–39].
TSA combines information size estimation for meta-analysis
(cumulated sample size of included trials) with an adjusted thresh-
old for statistical significance of meta-analysis [34,36,40]. The lat-
ter, called trial sequential monitoring boundaries (TSMB), reduce
type-I errors. In TSA the addition of each trial in a cumulative
meta-analysis is regarded as an interim analysis and helps toen from ClinicalKey.com by Elsevier on July 24, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
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is that when the cumulative z-curve crosses the TSMB, a sufficient
level of evidence has been reached and no further trials may be
needed. If the z-curve does not cross the boundary of benefit and
the required information size has not been reached, there may be
insufficient evidence to reach a conclusion [34,36,41,42]. TSA can
also be used for the evaluation of type II errors, that is, to evaluate
whether further randomized trials are futile to show or discard the
anticipated intervention effect (RRR or MD). This happens when
the cumulative z-curve does cross the TSMBs for futility. TSA will
be applied since it controls the risks of type-I and type-II errors
in a cumulative meta-analysis and may provide important infor-
mation on how many more patients need to be included in further
trials. The information size will be calculated as diversity-adjusted
required information size (DARIS) [43]. We will do the primary
analysis calculating the DARIS based on an a priori anticipated
intervention effect of a 10% RRR which is close to a minimal impor-
tant difference. We will conduct sensitivity analyses for a 15% RRR
as well as the RRR suggested by the meta-analysis of the included
trials [44]. If the estimated Diversity of the meta-analysis is 0%, a
sensitivity analysis with TSA using a Diversity of 25% will be con-
ducted. TSA will be performed on all outcomes. The required infor-
mation size for primary outcomes will be calculated based on an a
priori RRR of 10% and appropriately adjusted for diversity accord-
ing to an overall type-I error of 2.5% for the co-primary outcomes
and 3.3% for the secondary outcomes to account for a family wise
error (FWER) of 5% all in all, we will use a power of 90% considering
sparse data and repetitive testing [43]. For secondary outcomes the
DARIS will be calculated using a power of 90% [43]. As a sensitivity
analysis, the DARIS will be calculated using the estimated interven-
tion effect from the trials at low risk of bias in a conventional meta-
analysis. If the required information size is surpassed for the TSA
using the estimated intervention effect in the conventional meta-
analysis or a TSMB is crossed a TSA with an anticipated interven-
tion effect equal to the confidence limit closest to the null effect
in the effect estimate from the conventional meta-analysis will
be performed.
The TSAs will be conducted using the control event proportion
calculated from the unweighted control event proportion from
the control groups of the actual meta-analyses.2.22. Subgroup analyses
The following subgroup analysis will be performed:
Trials at overall low risk of bias (all except blinding of surgeons
scored as low risk of bias) compared to trials at high overall risk of
bias (two or more of the bias domains (including blinding of sur-
geons) scored as unclear or high risk).3. Grade
We will use summary of findings tables to summarize the
results of the trials with overall low risk of bias and for all trials,
separately. Reasons for downgrading the quality of the available
evidence are: risk of bias evaluation of the included bias domains,
publication bias, heterogeneity, imprecision, and indirectness (e.g.
length of stay is a surrogate outcome measure) [44–47]. We will
compare the imprecision assessed according to GRADE with that
of TSA [48].3.1. Patient and public involvement
Patients and/ or public were not involved in this study.Downloaded for Anonymous User (n/a) at University of Gron
For personal use only. No other uses without permissio3.2. Ethics and dissemination
The proposed systematic review will collect and analyze sec-
ondary data from already performed studies therefore ethical
approval is not required. The results of the systematic review will
be disseminated by publication in a peer-review journal and sub-
mitted for presentation at relevant conferences.
3.3. Protocol timeline
First registration of the protocol at Prospero CRD42019139913
in August 2019.
Proposed date of starting the search: 1st of January 2020. Pro-
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